Shareholder rights advocates at levi & korsinsky investigate vertex pharmaceuticals incorporated (vrtx) regarding possible securities fraud violations

New york, ny / accesswire / december 26, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of vertex pharmaceuticals incorporated ("vertex pharmaceuticals") (nasdaq:vrtx) concerning possible violations of federal securities laws. on december 19, 2024, the company reported disappointing results from its rewind-lb phase 2b clinical trial for the pain drug suzetrigine.
VRTX Ratings Summary
VRTX Quant Ranking